EVALUATION OF SOME VITAMINS RELATED WITH GLYCEMIC INDEX IN TYPE 2 DIABETES PATIENTS.

Mohanad S. AL-Fayyadh.
Dept of Biotechnology/college of science/Baghdad University/Iraq.

Abstract

Type 2 diabetes is the most common form and is characterized by the failure of cells to recognize and respond to insulin which is if not treated accurately. This study aims to evaluation of some vitamins related with glycemic index in type 2 diabetes patients. Twenty five patients suffering from diabetes mellitus conducted these investigations including some vitamins and biochemical parameters. The result revealed increasing level of FBS, HbA1c and cortisol hormone in diabetic subjects compared with control at \( P \) value <0.05. Decreasing level of vitamin E and vitamin D3 in diabetic subjects at \( P \) value <0.05.

Introduction:

Diabetes mellitus (DM) is a metabolic disease identify by hyperglycemia resulting from deficiency of insulin, insulin secretion or together (1). Diabetes has occur as one of the most important diseases worldwide, reaching epidemic proportions. Universal estimates predict that the proportion of adult population with diabetes will increase 69% for the year 2030 (2). Hyperglycemia in the procession of diabetes usually leads to the advancement of microvascular complications, and diabetic patients are more prone to atherosclerotic macrovascular disease. These complexity account for premature mortality and most of the social and economic burden in the long term of diabetes (3). Rising evidence suggests that oxidative stress plays a role in the pathogenesis of diabetes mellitus and its complexity (4). Hyperglycemia increases oxidative stress, which participate to the weakness of the major processes that fail during diabetes, insulin action and insulin secretion. In addition, antioxidant mechanisms are reduced in diabetic patients, which may further increase oxidative stress (5, 6). Several studies have addressed the possible contributes of dietary antioxidants, such as vitamins, in ameliorating the diabetic state and inhibited the development of diabetes complications (7). Type 2 diabetes is one of the main noncommunicable chronic diseases and its complications have become a major cause of morbidity and mortality worldwide. It has been estimated that 285 million individuals have diabetes, most of them type 2 diabetes (8).

Insulin resistance and progressive pancreatic \( \beta \)-cell dysfunction are well-established defects in the pathogenesis of type 2 diabetes (9). Tissue resistance to the action of insulin is believed to be a common antecedent to both type 2 diabetes and atherosclerotic disease (10-12). Much research has also demonstrated that both insulin resistance and hyperglycemia increase oxidative stress and thus accelerate the atherosclerotic process. Considerable evidence supports the theory that free radicals play an important role in the development of many chronic degenerative diseases of aging, including type 2 diabetes (13,14). Highly reactive free radicals can oxidize and damage such essential molecules as DNA, proteins, and lipids, and accumulation of damaged, oxidized, and dysfunctional peptides is one of the most fundamental manifestation of aging (13). To guard against oxidative damage caused by free radicals, two major defense mechanisms - the enzymatic (intracellular defense) and the non-enzymatic (intercellular defense) - are found in the human body. The antioxidants such as vitamin E and vitamin C constitute...
the primary intercellular defense against free radicals.(15,16) In laboratory research, vitamin C, vitamin E, and other antioxidants have been shown to prevent tissue damage by trapping organic free radicals and/or deactivating excited oxygen molecules, which are byproducts of many metabolic functions.(17) This antioxidant activity may slow or prevent atherosclerotic plaque formation by inhibiting oxidation of low-density lipoprotein cholesterol (LDL) and thus protecting the vascular wall from oxidized LDL and other cytotoxic oxidative products.(18) Vitamin E may also modify platelet activity,(19-21) reduce thrombotic potential,(22) and modify vascular reactivity(23-24) via antioxidant-related modifications in prostaglandin metabolism and nitric oxide production. Vitamin D deficiency and diabetes mellitus are two common conditions in the elderly population. Vitamin D deficiency is currently a topic of intense interest, and is widely prevalent across all ages, races, geographical regions, and socioeconomic strata. Suboptimal vitamin D status contributes to many conditions, including osteomalacia, osteoporosis, falls, and fractures (25,26). In addition, epidemiologic observations have associated low vitamin D status with an increased risk of non-musculoskeletal diseases, such as cancer (27), multiple sclerosis (28), type 1 diabetes mellitus (29), type 2 diabetes mellitus (30) and cardiovascular disease (31). Vitamin D is a generic name for a group of fat steroids of which the two major forms are vitamin D2 and vitamin D3. Both forms of vitamin D undergo identical metabolism. Vitamin D is obtained from skin irradiation and limited dietary sources. Vitamin D from the skin and diet is metabolized in the liver to 25(OH) D, which has a long life and is the major circulating metabolite and marker of vitamin D status (32). Various hormones, like, cortisol and growth hormone have insulin-repeated effects. During deficiency of glucose in the blood stream, these hormones are secreted to bring back blood glucose levels by stimulating glucose release from the liver and preventing glucose uptake in peripheral tissues. Increasing levels of these hormones can production insulin resistance and hyperglycemia. The effect of cortisol in the glucose and metabolism of lipid is to a large range opposite that of insulin. Hepatic glucose production is increased, while insulin stimulated glucose uptake in muscle and a fat tissue is weaken. High cortisol of endogenous origin can cause insulin resistance and in diabetic patients, this can lead to a determination of diabetic control (33). Cortisol change glucose level by affecting glucose transporters in peripheral tissues such as fat and skeletal muscle (34). So, cortisol can participate to increase blood glucose levels due to inactive uptake of glucose in the peripheral tissue. Cortisol may play an important role in the development of type 2 diabetes mellitus, it is possible that even little increase in cortisol within the extent of normal, may have a detrimental effect by worsening diabetes and increasing complexity (35).

Materials and method:
This study was carried out in the Department of Biotechnology, College of Science, University of Baghdad. Twenty five patients who either attended the diabetic clinic or were admitted in the department and suffering from diabetes mellitus.

Specific investigations like fasting blood sugar (FBS), glycated haemoglobin (HbA1c). Serum vitamin E (S.VITE), Serum vitamin D (S.VITD3) and Serum Cortisol was carried out in this study. Samples were collected. Analysis of the samples was accomplished in the Chemical Laboratory, University of Baghdad. Collage of Science. Department of Biotechnology. in the morning from the subjects Blood samples were collected after 16 hours fasting. A syringe and needle was used to collect 5ml of blood sample from the subjects.

Determination of Serum Vitamin E:
Serum Vitamin E determined by ELISA Kit for Human Vitamin E (VE). Cat.No:E0922Hu.

Determination of Serum Vitamin D:
Serum Vitamin D determined by ichroma Kit Human Vitamin D No:INS-VD-EN(Rev.00)

TEST PRINCIPLE: The test uses a competitive immune detection method in this method, the target material in the sample bind to the fluorescence (FL)-labeled detection antibody in detection buffer, to form the complex as sample mixture. This complex is loaded to migrate onto the nitrocellulose matrix, where the covalent couple 25(OH)D3 and bovine serum albumin (BSA) is immobilized on a test strip, and interference with the binding of target material and FL-Labeled antibody. If the more target material exists in blood, the less detection antibody is accumulated, resulting in the less fluorescence signal.
Serum Cortisol was determined by competitive immune detection method by ichroma kit. Fasting blood sugar was estimated enzymatically by using glucose oxidase GOD PAP(Kit)(Liquid)GL2624. Glycated hemoglobin (HbA1c) was determined by (StanbioGlycohemoglobin –pre-fil-procedure No.P350) quantitative colorimetric determination of Glycohemoglobin in whole blood.

The data generated was resolved using statistical software SPSS 17.0, was used for analysis of differences between means for two groups. Pearson correlations were proceed to determine associations between different variables. A scatter plot graph was conducted using Microsoft excel 2010.

**Results and Discussion:**
A total of twenty-five (25) patients suffering from diabetes mellitus were recruited to the study. In (Table 1) shows the comparison of means of biochemical parameters between type 2 diabetics and control subjects.

| Parameters     | Control Subject | Type 2 Diabetic Subject | P-Value |
|----------------|-----------------|-------------------------|---------|
| FBS mg/dl      | 95 ±10          | 194.12 ±43.90           | <0.05   |
| HbA1c %        | 5.4 ±0.45%      | 8.4 ±1.87               | <0.05   |
| S.VIT E mg/dl  | 1.25 ±0.18      | 0.60 ±0.16              | <0.05   |
| S.VITD3 mg/L   | 28 ±5.3         | 17.53 ±4.18             | <0.05   |
| S. Cortisolng/ml| 8.4 ±2.3        | 12.02 ±3.2              | <0.05   |

Mean + SEM

This work examined the degree of involvement of some biochemical parameters in the complications of diabetes mellitus. Fasting blood sugar (FBS), glycated heamoglobin (HbA1c), Serum vitamin E (S.VIT E), Serum vitamin D3 (S.VITD3) and cortisol hormone were examined. Fasting blood sugar (FBS), HbA1c and Cortisol was found at significantly higher (p <0.05) concentration in the sera of type 2 diabetics when compared with controls. The value found in this study may be a contributor to the diabetic condition.

Elevated cortisol is associated with increase in hepatic gluconeogenesis and glycogenolysis and consequently with hyperglycemia. Cortisol is a glucocorticoid, the function of which is to ensure that blood glucose level remains elevated. Its role in diabetes mellitus may however be undesirable as it turns to sustain hyperglycemia. This finding points to the need to measure this hormone in diabetics as part of monitoring and control.

Elevated cortisol is associated with increase in hepatic gluconeogenesis and glycogenolysis and consequently with hyperglycemia. Cortisol is a glucocorticoid, the function of which is to ensure that blood glucose level remains elevated. Its role in diabetes mellitus may however be undesirable as it turns to sustain hyperglycemia. This finding points to the need to measure this hormone in diabetics as part of monitoring and control.

Cortisol alters blood glucose by affecting glucose transporters in peripheral tissues such as fat and skeletal muscle (36).

Cortisol has also been linked to obesity (37). It stimulates hepatic triglycerides synthesis (38), increases the number of adipocytes in the visceral depots and stimulates appetite and hence obesity (39). It also induces insulin resistance probably by antagonizing effect of insulin (40).
Fig 2: shows concentration of Fasting blood sugar (FBS) in diabetics and control subjects. In our study as clinical trial we showed increased significant in (FBS) in diabetic subjects compared with control.

Our study also shows vitamin D levels tend to be lower in diabetics. The mean FBS value in patients with vitamin D was higher than in cases with optimal vitamin D levels. The inverse relationship between vitamin D levels and FBS in diabetics was also seen in other studies. In a study done at Sree Balaji Medical College and Hospital, Chrompet, Chennai, on 50 cases of type 2 diabetics the mean vitamin D level was 18.492 with mean FBS value being 146.22 mg/dl. Chiu et al., 2004 serum 25(OH) D3 is positively correlated with ISI and negatively correlated with post-prandial glucose concentration (41).

Fig 3: shows concentration of serum vitamin D3 (S.VITD3) in control and diabetics subjects.

Fig 4: shows value of glycated hemoglobin (HbA1c %) in control and diabetics subjects.
In diabetics the mean HbA1C levels were higher in vitamin D deficient patients compared to those with optimal levels of vitamin D levels. Additionally HbA1c levels were higher in patients with severe vitamin D deficiency when compared to subjects with mild to moderate deficiency. The inverse association between vitamin D and HbA1c is similar to other studies. The study conducted by Dalgard and associates on 668 Faroese residents, where an increasing concentration of HbA1c was associated with decreasing levels of vitamin D levels. This was independent of sex, smoking status, body habitus (42).

Fig 5: shows concentration of serum vitamin E (S.VITE) in control and diabetics subjects.

Serum vitamin E level was 0.60 mg/dl (SD 0.16) in cases of diabetes mellitus while it was 1.25 mg/dl (SD 0.18) in control subjects. This decrease in levels of VIT E in cases of diabetes mellitus was highly significant (< 0.05). It suggests that they have suffered more oxidative stress than control subjects.

Polidori et al8 who have estimated VIT E level in 72 type-2 diabetic patients and 75 normal healthy controls. The level of VIT E was 18.6 (SD 1.2) micromol/l in diabetic patients and was 26.8 micromol/l (SD 1.0) in control subjects. When compared, this decrease of VIT E in type-2 diabetic subjects was statistically highly significant (p< 0.001) (43). Our observation also supports this fact.

Fig 6: Correlation of level of glycated Hemoglobin (HbA1c) and serum vitamin D (S.VITD) level.
Although we found a significant association of both FBS and HbA1c with severe 25(OH)D deficiency and vitamin E, similar findings have been reported inconsistently in previous work. While an inverse association of 25(OH)D and FBS has been observed several times in different populations (44,45,46), inverse associations with HbA1c were not detected in younger Americans (45) but detected in older Germans (44). There are several lines of evidence to support that vitamin D influences impaired β-cell function, insulin resistance and systemic inflammation (47). It has been demonstrated that vitamin D receptor exist in many tissues including pancreatic β-cells (48), allowing vitamin D to potentially modulate the insulin response to elevated blood glucose.
Conclusion:-
This study has found abnormally raised level of serum cortisol, fasting blood sugar (FBS) and glycated hemoglobin (HbA1c) with decreased level of Vitamin E and Vitamin D3 in type 2 diabetics subjects. Vitamin D and Vitamin E deficiency is a risk factor for development of type 2 diabetes mellitus. There might be potential beneficial role of vitamin D and E supplementation and improving glycemic status in type 2 diabetics.

References:
1. ADA. (2009). Diagnosis and classification of diabetes mellitus. Diabetes care, 32(1), 62-7.
2. Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract, 87(1), 4-14.
3. King, H., Aubert, R. E., & Herman, W. H. (1998). Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 21(9), 1414-1431.
4. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865), 813-820.
5. Rains, J. L., & Jain, S. K. (2011). Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med, 50(5), 567-575.
6. Maritim, A. C., Sanders, R. A., & Watkins, J. B. (2003). Diabetes, oxidative stress, and antioxidants: A review. Journal of Biochemical and Molecular Toxicology, 17(1), 24.
7. Sheikh-Ali, M., Chehade, J. M., & Mooradian, A. D. (2011). The antioxidant paradox in diabetes mellitus. Am J Ther, 18(3), 266-278.
8. International Diabetes Federation (IDF). Diabetes Atlas Global Burden, Epidemiology and Morbidity. Diabetes and Impaired Glucose Tolerance. Available online: http://www.diabetesatlas.org/ content/diabetes-and-impaired-glucose-tolerance (accessed on 19 October 2011).
9. Kahn CR. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994;43:1066 1084.
10. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 1979;2:131-141.
11. Stout RW. Insulin and atheroma.20-yr perspective. Diabetes Care. 1990;13:631-654.
12. Stern MP. Diabetes and cardiovascular disease: the 'common soil' hypothesis. Diabetes. 1995;44:369-374.
13. Ames B, Shigenaga M, Hagen T. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA. 1993;90:7915-7922.
14. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet. 1994;344:721-724.
15. Frei B. Ed. Natural antioxidants in human health and disease. New York, Academic Press. 1994.
16. Frei B. Reactive oxygen species and antioxidant vitamins: mechanisms of action. Am J Med. 1994;97:5S-13S.
17. Packer L. Protective role of vitamin E in biological systems. Am J Clin Nutr. 1991;53:1050S-1055S.
18. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation. 1991;84:1420-1425.
19. Harris MI. Prevalence of noninsulin-dependent diabetes and impaired glucose tolerance. In: National Diabetes Data Group, eds. Diabetes in America: Diabetes data compiled 1984. U.S. Department of Health and Human Services publication (PHS) 85-1468. National Institutes of Health. 1985; VI 1-31.32.
20. Manson J, Spelsberg A. Primary prevention of non-insulin-dependent diabetes mellitus. Am J Prev Med. 1994;10:172-184.
21. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch Willett WC. Nutritional Epidemiology, Second Edition. New York: Oxford University Press; 1998.
22. Salonen JT, Nyyssonen K, Tuomainen TP, et al. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. BMJ. 1995;311:1124-1127.
23. Will JC, Byers T. Does diabetes mellitus increase the requirement for vitamin C? Nutrition Rev. 1996;54:193-202.
24. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004; 79(3):362-71.
25. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee Ry, et al. Effect of vitamin D on falls: a metaanalysis. JAMA. 2004;291(16):1999-2006.
26. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006;96(2):252-61.
27. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832-8.
28. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes: state of the art. Trends Endocrinol Metab. 2005;16(6):261-6.
29. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxyvitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes. 2008;57(10):2619-25.
30. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-23.
31. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(6):1689S-96S.
32. Orskov, L., Schmitz, O. & Bak, J. F. (2001). Skeletal Muscle glucose uptake, glycogen synthase activity and Glu T4 content during hypoglycemia in type 1 diabetic subjects. Scand Journal of Clinical Laboratory and Investigation, 61 (5), 371-381 (cortisol)
33. Tracey, L. (2010). The role of cortisol and abdominal obesity in the epidemic of type 2 diabetes. Retrieved July 21, 2011 from http://www.kon.ucr/v9/lieberman.html (cortisol) Mathews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., & Turner, R. C. (1985). Homeostasis model assessment: Insulin resistance and glucose disposal. Diabetologia, 28, 412-419
34. Weststrate, J. A., Dekker, J., Stoel, M. & Hautvast, J. G. (1990). Resting energy expenditure in women: Impact of obesity and blood fat distribution. Metabolism, 39, 11-17
35. Klausner, H. & Heimberg, M. (1967). Effect of adrenocortical hormones on release of triglycerides and glucose by liver. American Journal of Physiology, 212, 1236-1246
36. King, B. M., Banta, A. B., Tharel, G. N., Bruce, B. L. & Frohman, L. A. (1999). Hypothalamic Hyperinsulinemia and obesity: role of adrenal glucocorticoids. American Journal of Physiology, 245, 194 199
37. Cigolini, M. & Smith, U. (1979). Human adipose tissue in culture viii. Studies on the insulin antagonistic effect of glucocorticoids. Metabolism, 28, 502-510
38. Chiu KC, Chu A, Go VL, Saad MF; Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr., 2004; 7(5): 8205.
39. Dalgård C, Petersen MS, Weihe P, Grandjean P; Vitamin D Status in relation to glucose metabolism and type 2 diabetes in septuagenarians. Diabetes Care, 2011; 34(6):1284-1288.
40. Polidori MC et al. Plasma levels of lipophilic antioxidants in very old patients with type-2 diabetes. Diabetes Metab Res Rev 2000; 16: 15-9.
41. O’Hartaigh B, Neil Thomas G, Silbernagel G, Bosch JA, Pilz S, Loerbroks A, et al. Association of 25 hydroxyvitamin D with type 2 diabetes among patients undergoing coronary angiography: cross sectional
findings from the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. ClinEndocrinol. 2013;79:192–98.
44. Ford ES, Zhao G, Tsai J, Li C. Associations between concentrations of vitamin D and concentrations of insulin, glucose, and HbA1c among adolescents in the United States. Diabetes Care. 2011;34:646–48.
45. Husemoen LLN, Thuesen BH, Fenger M, Jørgensen T, Glümer C, Svensson J, et al. Serum 25(OH)D and type 2 diabetes association in a general population: a prospective study. Diabetes Care. 2012;35:1695 700.
46. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2007;92:2017–29.
47. Anagnostis P, Athyros VG, Adamidou F, Florentin M, Karagiannis A. Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? CurrVascPharmacol. 2010;8:720–30.